News

A deeper dive into anti-VEGF loss to follow-up: Study identifies risk factors

Where are the women in retina? Not at the podium, study reports

Bevacizumab first, aflibercept second cost-effective for DME, Protocol AC finds

With Byooviz, Biogen takes a leap on pricing first U.S. retina biosimilar

New DME treatment trial targets underrepresented populations

A deeper dive into why DAZZLE results of KSI-301 in nAMD ‘disappointed’

Retina Update: Is Vabysmo the next $1 billion anti-VEGF?

Retina Update: Market forces may be gathering to exert price pressures on anti-VEGF drugs

Retina Update: New research challenges previous findings on genetic risk factor for AMD

Retina Update: Finnish researchers add voice to cataract surgery in AMD debate

Load More